Clinical Trial Update: First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study evaluating safety, tolerability, and pharmacokinetics of intravenous ATB200 alone and when co-administered with oral AT2221 in Pompe diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• AT2221
• ATB200

Snippet

Sponsor: Amicus Therapeutics | Conditions: Pompe Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-10-23